H. Lundbeck ASHLUBF 78 Dividend Payout Ratio is 0.69 as of Mar. 2026, which is 176% above its 10-year median of 0.25. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review. Among 444 Drug Manufacturers companies, H. Lundbeck AS ranks better than 60.36% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. H. Lundbeck AS's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.69.
The historical rank and industry rank for H. Lundbeck AS's Dividend Payout Ratio or its related term are showing as below:
HLUBF'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.25 Med: 0.25 Max: 0.31
Current: 0.31
During the past 13 years, the highest Dividend Payout Ratio of H. Lundbeck AS was 0.31. The lowest was 0.25. And the median was 0.25.
HLUBF's Dividend Payout Ratio is ranked better than 60.36% of 444
companies
in the Drug Manufacturers industry
Industry Median: 0.375
vs HLUBF: 0.31
During the past 12 months, H. Lundbeck AS's average Dividends Per Share Growth Rate was 21.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
H. Lundbeck AS (OTCPK:HLUBF) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
H. Lundbeck AS Dividend Payout Ratio Related Terms
H. Lundbeck AS Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLUBF vs ZTS, UTHR, VTRS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
H. Lundbeck AS's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (HLUBF) has a Dividend Payout Ratio of 0.69 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on H. Lundbeck AS and its competitors. This is 176% above median its historical median of 0.25. Over the past decade, H. Lundbeck AS's Dividend Payout Ratio has ranged from 0.25 to 0.31. According to the industry distribution chart, H. Lundbeck AS ranks #176 out of 444 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is H. Lundbeck AS's Dividend Payout Ratio too high?
H. Lundbeck AS's current Dividend Payout Ratio of 0.69 is 176% above median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.31. The Drug Manufacturers industry median Dividend Payout Ratio is 0.38. H. Lundbeck AS's value of 0.69 is 84% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #176 out of 444 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #176 out of 444 companies for Dividend Payout Ratio. This puts H. Lundbeck AS in the upper half of its industry. The industry median Dividend Payout Ratio is 0.38. H. Lundbeck AS's value of 0.69 is 84% above this benchmark. Historically, H. Lundbeck AS's own Dividend Payout Ratio has ranged from 0.25 to 0.31 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.38, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current Dividend Payout Ratio of 0.69 is 84% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current Dividend Payout Ratio is 0.69, which is 176% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current Dividend Payout Ratio is 0.69, which is 176% above median its 10-year median of 0.25 and 84% above the Drug Manufacturers industry median of 0.38. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current Dividend Payout Ratio is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (HLUBF) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for HLUBF:
Dividend Payout Ratio: 0.69 (176% above median its 10-year median of 0.25)
GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
Industry Position: 84% above the Drug Manufacturers median (#176 of 444)
No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score
Get the complete analysis for HLUBF
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLUBF has been successfully added to your 
